New look. Same commitment. Decision Resources Group becomes Clarivate. Read more here
For biotech and pharma teams serving smaller patient populations, such as those with rare diseases and sub-indications, there are a number of unique hurdles to getting the intelligence needed to deliver new treatments and improve patient outcomes. |
However, some brands are getting creative with real-world data and analytics strategies in order to better understand true market need, friction points in the patient experience and factors driving outcomes.
In this Conversations in Healthcare panel, DRG's Mike Ward joined industry experts to discuss:
- Challenges in understanding niche markets, patient characteristics and patient experience
- Implications for clinical and commercial decisions and patient outcomes
- Real-world data approaches and analytics strategies
- Success stories and learnings
- Key takeaways for biotech and pharma teams
Panelist Information
Mike Ward
Global Head of Thought Leadership
Ryan Rumantir
Director, Client Engagement
Dr. Srikanth (Doc) Rajagopal
Partner DRG Consulting
Jacqueline Lyons, MPH
Director of Epidemiology at Alexion Pharmaceuticals
